MSPharma

MSPharma operates under that alias as a pharmaceutical company headquartered in Jordan. It is understood to be a subsidiary or division of the larger United Pharmaceutical Manufacturing Co., which is referenced as its parent entity in reporting about a cyber incident. The organisation functions within the pharmaceutical sector, which encompasses the research, development, manufacturing, and distribution of medicines and related healthcare products. While specific details of its product portfolio or market reach are not disclosed in the available sources, its classification as a pharmaceutical firm places it within an industry that serves both domestic and international health markets. The company’s organisational structure ties it to United Pharmaceutical Manufacturing Co., indicating a hierarchical relationship where MSPharma likely benefits from the parent’s resources, regulatory expertise, and distribution networks.

In April 2021, MSPharma became the target of a cyberattack claimed by the Avaddon ransomware group. According to the report, threat actors leaked files that were said to belong to its parent entity, United Pharmaceutical Manufacturing Co., suggesting that the breach extended beyond the subsidiary’s immediate systems. The leaked data reportedly included internal company files, although the full scope and impact of the compromise remained unconfirmed because MSPharma did not respond to verification attempts at the time of the incident’s disclosure. This event was noted alongside a separate ransomware attack on the Milan‑based Mipharm SPA attributed to the Sodinokibi (REvil) group, though the two incidents were distinct in their targets and claimed perpetrators.

The Avaddon claim highlighted the growing threat that ransomware poses to pharmaceutical organisations, which often hold valuable intellectual property, clinical data, and supply‑chain information. The lack of a response from MSPharma to verification requests left external observers unable to validate the authenticity or extent of the leaked material, a common challenge in early‑stage breach reporting. Despite the uncertainty, the episode underscored the importance of robust cybersecurity measures for companies operating in the healthcare and pharmaceutical sectors, particularly those with international affiliations.

Overall, MSPharma’s identity as a Jordan‑based pharmaceutical entity linked to United Pharmaceutical Manufacturing Co. is defined primarily by its sector role and the notable ransomware incident of April 2021. The available information does not provide quantitative metrics on its size, workforce, or market share, so those aspects remain unspecified. What is clear is that the organisation’s experience with a cyber extortion attempt reflects broader vulnerabilities faced by pharmaceutical firms worldwide, reinforcing the need for vigilant threat monitoring and incident response capabilities.